Clinical Trials
12 trialsNCT00588770 2026-05-29
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04620187 2026-04-13
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT03781986 2026-03-03
APG-115 in Salivary Gland Cancer Trial
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT05010629 2025-05-31
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT01847326 2024-07-31
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
University of Chicago
Phase 1 Completed
NCT00079079 2023-08-04
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
Canadian Cancer Trials Group
Phase 2 Completed
NCT04832438 2022-02-22
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Actuate Therapeutics Inc.
Phase 2 Withdrawn
NCT01249443 2020-07-29
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
AIDS Malignancy Consortium
Phase 1 Terminated
NCT01316757 2018-02-26
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00022217 2013-12-18
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00021047 2012-03-08
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed